Treatment implications on morbidity and mortality in COPD

Chest

Volumn 126, Issue 2 SUPPL., 2004, Pages 150S-158S

  Mapel, Douglas W ^{a,b,c,d,e,f,g}  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b ASTRAZENECA   (United Kingdom)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d GLAXOSMITHKLINE   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

^f PFIZER INC   (United States)

^g LOVELACE CLINIC FOUNDATION   (United States)

Author keywords

Asthma; Chronic bronchitis; COPD; Epidemiology; Inhaled corticosteroids; Treatment outcome

Indexed keywords

CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; SALBUTAMOL; SALMETEROL;

ASTHMA; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; EMPHYSEMA; HUMAN; MORBIDITY; MORTALITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SURVIVAL; TREATMENT OUTCOME;

EID: 4143127780     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.126.2_suppl_1.150S     Document Type: Article

References (41)

1. Barnes P. Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161:342-344
2. Calverley PMA. Inhaled corticosteroids are beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161:341-342
3. Postma DS, Kerstjens HA. Are inhaled glucocorticosteroids effective in chronic obstructive pulmonary disease? Am J Respir Crit Care Med 1999; 160:S66-S71
4. Hattotuwa KL, Gizycki MJ, Ansari TW, et al. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med 2002; 165:1592-1596
5. Balbi B, Majori M, Bertacco S, et al. Inhaled corticosteroids in stable COPD patients: do they have effects on cells and molecular mediators of airway inflammation? Chest 2000; 117:1633-1637
6. Confalonieri M, Mainardi E, Della Porta R, et al. Inhaled corticosteroids reduce neutrophilic inflammation in patients with chronic obstructive pulmonary disease. Thorax 1998; 53:583-585
7. Llewellen-Jones CG, Hams AT, Stockley RA. Effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema. Am J Respir Crit Care Med 1996; 153:616-621
8. Thompson AB, Mueller MB, Heires AJ, et al. Aerosolized beclomethasone in chronic bronchitis. Am Rev Respir Dis 1992; 146:389-395
9. Culpitt SV, Maziak W, Loukidis S, et al. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160:1635-1639
10. Keatings VM, Collins PD, Scott DM, et al. Differences in interleukin-8 and tumor necrosis factor-α in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996; 153:530-534
11. Vestbo J, Sorensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353:1819-1823
12. Pauwels RA, Löfdahl CG, Laitinen LA, et al, for the European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999; 340:1948-1953
13. Burge PS, Calverley PMA, Jones PW, et al, on behalf of the ISOLDE study investigators. Randomised, double-blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320:1297-1303
14. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343:1902-1909
15. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the discus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166:1084-1091
16. Calverley P, Pauwels R, Vestbo J, et al, for the TRISTAN study group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361:449-456
17. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21:74-81
18. Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003; 124:834-843
19. Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164:580-584
20. Soriano JB, Vestbo J, Pride NB, et al. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 2002; 20:819-825
21. Sin DD, Man SF. Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter? Eur Respir J 2003; 21:260-266
22. Samet JM. Measuring the effectiveness of inhaled corticosteroids for COPD is not easy! Am J Respir Crit Care Med 2003; 168:1-2
23. Piquette CA, Rennard SI, Snider GL. Chronic bronchitis and emphysema. In: Murray JF, Nadel JA, Mason RJ, et al, eds. Textbook of respiratory medicine, 3rd ed. Philadelphia, PA: WB Saunders Company, 2000; 1187-1244
24. Celli BR, Snider GL, Heffner J, et al. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152:S77-S120
25. Pauwels RA, Buist AS, Calverley PMA, et al, on behalf of the GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001; 163:1256-1276
26. Gross NJ. Outcome measurements in COPD: are we schizophrenic? Chest 2003; 123:1325-1327
27. Bousquet J, Jeffery PK, Busse WW, et al. Asthma: from bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000; 161:1720-1745
28. Suissa S, Ernst P. Inhaled corticosteroids: impact on asthma morbidity and mortality. J Allergy Clin Immunol 2001; 107:937-944
29. Kips JC, Pauwels RA. Low dose inhaled corticosteroids and the prevention of death from asthma. Thorax 2001; 56(suppl 2):ii74-ii78
30. Soriano JB, Davis KJ, Coleman B, et al. The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. Chest 2003; 124:474-481
31. Mapel DW, Picchi MA, Hurley JS, et al. Utilization in COPD: patient characteristics and diagnostic evaluation. Chest 2000; 117:346S-353S
32. Waterhouse JC, Fishwick D, Anderson JA, et al. What caused death in the Inhaled Steroids in Obstructive Lung Disease in Europe (ISOLDE) study [abstract]? Eur Respir J 1999; 14(suppl 30):387S
33. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000; 342:1878-1886
34. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342:1887-1892
35. Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med 2003; 168:49-53
36. Fan VS, Bryson CL, Curtis JR, et al. Inhaled corticosteroids in chronic obstructive pulmonary disease and risk of death and hospitalization. Am J Respir Crit Care Med 2003; 168:1488-1494
37. Sin DD, Tu JV. Inhaled glucocorticoids in COPD: immortal time bias. Am J Respir Crit Care Med 2003; 168:126-127
38. Fisher LD, Lin DY. Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Public Health 1999; 20:145-157
39. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341:410-418
40. Calverley PMA, Burge PS, Spencer S, et al, for the ISOLDE Study Investigators. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003; 58:659-664
41. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152:S77-S120